Subscribe X
Back to Top



November 19, 2013 by Sandra Steingard, MD

Tapering Neuroleptics: Two Year Results

Sandra_Steingard_MDAs I have described previously, I have been tracking my experience with tapering neuroleptic drugs in my clinical practice. With all of the people I see who are stable on a particular dose of a neuroleptic drug, I discuss the risks of long-term use of these drugs. We also discuss the potential benefits.  This conversation varies from person to person. We take into account what has happened in the past,  how he is doing now, and what she has to lose if her past problems were to re-emerge.  If a person wants to taper, I suggest slow reduction; 25-30% every 3-6 months.  I keep track of who chooses to taper and who does not.  I now have a colleague who is doing the same in her practice.   Together, we are following 112 individuals. We presented our data in a poster presentation at the Institute of Psychiatric Services in October, 2013.

Read More

September 9, 2013 by Sandra Steingard, MD

Taking Anti-Psychotics When You Are Not Psychotic

Sandra_Steingard_MDIn brief, the Wunderink study uses a randomized control design and found that, in adults diagnosed with a psychotic disorder, continuous use of neuroleptics was associated with worse functional outcomes than intermittent use. Higher doses were associated with worse outcomes than lower ones.

These days, neuroleptic drugs are widely promoted to treat depression and they are often used “off-label” to treat behavioral problems in children. They are among the most widely prescribed drugs; given the theory that “schizophrenia” affects 1% of the population, it is clear that many individuals – adults and children – who do not have this diagnosis are prescribed these drugs.

Is the Wunderink study relevant to those who do not experience psychosis?

Read More

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.